These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7758661)

  • 1. Defining the ligand-binding site for vasopressin receptors: a peptide mimetic approach.
    Howl J; Parslow RA; Wheatley M
    Biochem Soc Trans; 1995 Feb; 23(1):103-8. PubMed ID: 7758661
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of acidic amino acid residues in the binding of ligands to the V1a vasopressin receptor.
    Davies AR; Wheatley M
    Biochem Soc Trans; 1995 Feb; 23(1):85S. PubMed ID: 7758805
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.
    Howl J; Wheatley M
    Biochem J; 1996 Jul; 317 ( Pt 2)(Pt 2):577-82. PubMed ID: 8713088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors.
    Rodrigo J; Pena A; Murat B; Trueba M; Durroux T; Guillon G; Rognan D
    Mol Endocrinol; 2007 Feb; 21(2):512-23. PubMed ID: 17082326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass-spectrometry-based method for screening of new peptide ligands for G-protein-coupled receptors.
    Cologna CT; Gilles N; Echterbille J; Degueldre M; Servent D; de Pauw E; Quinton L
    Anal Bioanal Chem; 2015 Jul; 407(18):5299-307. PubMed ID: 25935673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serine cluster prevents recycling of the V2 vasopressin receptor.
    Innamorati G; Sadeghi HM; Tran NT; Birnbaumer M
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2222-6. PubMed ID: 9482866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationships between receptor binding capacity for norepinephrine, angiotensin II, and vasopressin and release of inositol trisphosphate, Ca2+ mobilization, and phosphorylase activation in rat liver.
    Lynch CJ; Blackmore PF; Charest R; Exton JH
    Mol Pharmacol; 1985 Aug; 28(2):93-9. PubMed ID: 2991741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of linear analogues of vasopressin generated by the systematic substitution of positions 1 and 6 by L-amino acids.
    Howl J; Filer AD; Parslow RA; Kirk CJ; Jurzak M; Smith AI; Wheatley M
    Biochem Pharmacol; 1994 Apr; 47(9):1497-501. PubMed ID: 8185660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescent and biotinylated linear peptides as selective bifunctional ligands for the V1a vasopressin receptor.
    Howl J; Wang X; Kirk CJ; Wheatley M
    Eur J Biochem; 1993 Apr; 213(2):711-9. PubMed ID: 8477743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling.
    Postina R; Kojro E; Fahrenholz F
    Adv Exp Med Biol; 1998; 449():371-85. PubMed ID: 10026828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel dual angiotensin II/vasopressin receptor.
    Ruiz-Opazo N
    Nephrologie; 1998; 19(7):417-20. PubMed ID: 9857377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Three-Site Mechanism for Agonist/Antagonist Selective Binding to Vasopressin Receptors.
    Saleh N; Saladino G; Gervasio FL; Haensele E; Banting L; Whitley DC; Sopkova-de Oliveira Santos J; Bureau R; Clark T
    Angew Chem Int Ed Engl; 2016 Jul; 55(28):8008-12. PubMed ID: 27184628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors.
    Mouillac B; Phalipou S; Cotte N; Balestre MN; Hibert M; Manning M; Barberis C
    Adv Exp Med Biol; 1998; 449():359-61. PubMed ID: 10026825
    [No Abstract]   [Full Text] [Related]  

  • 14. Vasopressin and angiotensin control the activity of liver phosphodiesterase.
    Keppens S; De Wulf H
    Biochem J; 1984 Aug; 222(1):277-80. PubMed ID: 6089761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
    Cotte N; Balestre MN; Aumelas A; Mahé E; Phalipou S; Morin D; Hibert M; Manning M; Durroux T; Barberis C; Mouillac B
    Eur J Biochem; 2000 Jul; 267(13):4253-63. PubMed ID: 10866830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists.
    Hawtin SR; Wesley VJ; Parslow RA; Simms J; Miles A; McEwan K; Wheatley M
    Mol Endocrinol; 2002 Mar; 16(3):600-9. PubMed ID: 11875119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric strategies for the rational design of bioactive analogs of small peptide hormones.
    Howl J; Langel U; Hawtin SR; Valkna A; Yarwood NJ; Saar K; Wheatley M
    FASEB J; 1997 Jun; 11(7):582-90. PubMed ID: 9212082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen phosphorylase, glucose output and vasoconstriction in the perfused rat liver. Concentration-dependence of actions of adrenaline, vasopressin and angiotensin II.
    Hems DA; Rodrigues LM; Whitton PD
    Biochem J; 1976 Nov; 160(2):367-74. PubMed ID: 827289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine vasopressin antagonism of oxytocin-stimulated PGE2 release from rabbit amnion cells and the activities of thioanalogs of oxytocin and arginine vasopressin.
    Czaja M; Kruszyński M; Hinko A; Soloff MS
    Pol J Pharmacol; 1994; 46(5):429-37. PubMed ID: 7894530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The study of neurohypophyseal hormone receptors by ligand binding.
    Wheatley M; Howl J; Davies AR; Parslow RA
    Biochem Soc Trans; 1994 Feb; 22(1):113-8. PubMed ID: 8206202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.